Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

update structure and content of diagnostics section #1076

Merged
merged 25 commits into from
Jan 6, 2022
Merged
Show file tree
Hide file tree
Changes from all commits
Commits
Show all changes
25 commits
Select commit Hold shift + click to select a range
b397051
text structure and minor edits
jessegmeyerlab Dec 29, 2021
31d53f4
Update 10.diagnostics.md
jessegmeyerlab Dec 29, 2021
67eddfc
Update 10.diagnostics.md
jessegmeyerlab Dec 29, 2021
98229e0
Update 10.diagnostics.md
jessegmeyerlab Dec 30, 2021
68f1b66
accepted change 1
jessegmeyerlab Jan 2, 2022
969d3f1
accepted change 2
jessegmeyerlab Jan 2, 2022
a47457f
accepted change 3
jessegmeyerlab Jan 2, 2022
c33b6e6
accepted change 4
jessegmeyerlab Jan 2, 2022
7ebd97c
Update content/10.diagnostics.md
jessegmeyerlab Jan 2, 2022
aedc603
Update content/10.diagnostics.md
jessegmeyerlab Jan 2, 2022
b64f8b3
Update content/10.diagnostics.md
jessegmeyerlab Jan 2, 2022
f50dfbc
Update content/10.diagnostics.md
jessegmeyerlab Jan 2, 2022
e4889bd
Update content/10.diagnostics.md
jessegmeyerlab Jan 2, 2022
e9e66b5
Update content/10.diagnostics.md
jessegmeyerlab Jan 2, 2022
fad6739
Update content/10.diagnostics.md
jessegmeyerlab Jan 2, 2022
b9132a1
Update content/10.diagnostics.md
jessegmeyerlab Jan 2, 2022
e3d17a8
Update content/10.diagnostics.md
jessegmeyerlab Jan 5, 2022
d0033d8
Merge branch 'master' into patch-1
rando2 Jan 6, 2022
4f8d429
Update content/10.diagnostics.md
RLordan Jan 6, 2022
a8300a6
Update content/10.diagnostics.md
RLordan Jan 6, 2022
8d24233
Update content/10.diagnostics.md
RLordan Jan 6, 2022
2c0363a
Update content/10.diagnostics.md
RLordan Jan 6, 2022
702c57d
Update content/10.diagnostics.md
RLordan Jan 6, 2022
12e9808
Update content/10.diagnostics.md
RLordan Jan 6, 2022
e0e44d5
Update metadata.yaml
rando2 Jan 6, 2022
File filter

Filter by extension

Filter by extension

Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
86 changes: 69 additions & 17 deletions content/10.diagnostics.md
Original file line number Diff line number Diff line change
Expand Up @@ -13,18 +13,21 @@ For instance, test-trace-isolate procedures were an early cornerstone of many na
<!-- To Do: possibly add text on what goes into developing new diagnostics?-->

The genetic sequence of the virus was first released by Chinese officials on January 10, 2020, and the first test to detect the virus was released about 13 days later [@doi:10.2807/1560-7917.ES.2020.25.3.2000045].
This information is important to the development of diagnostic approaches using a variety of approaches.
This information is important to the development of diagnostic approaches.
There are two main classes of diagnostic tests: molecular tests, which can diagnose an active infection by identifying the presence of SARS-CoV-2, and serological tests, which can assess whether an individual was infected in the past via the presence or absence of antibodies against SARS-CoV-2.
Molecular tests are essential for identifying individuals for treatment and alerting their contacts to quarantine and be alert for possible symptoms.
Here, a patient sample is evaluated to determine the presence or absence of a viral target.
These techniques depend on knowledge of the viral genomic sequence for the development of targeted primers.
On the other hand, serological tests are useful for collecting population-level information for epidemiological analysis, as they can be used to estimate the extent of the infection in a given area.
Thus, they may be useful in efforts to better understand the percent of cases that manifest as severe versus mild and for guiding public health and economic decisions regarding resource allocation and counter-disease measures.
These tests typically detect the presence of antibodies in blood plasma samples.
In such enzyme-linked immunosorbent assay (ELISA) approaches, the detection of the antibodies depends on knowledge of a specific antibody-antigen interaction.
As the pandemic has evolved throughout 2020 and 2021, a variety of tests have emerged within these two categories.

Molecular tests detect either viral RNA or protein in a patient sample.
Molecular tests are essential to identify infected individuals who may need to seek treatment, quarantine, and whose contacts may need to quarantine.
Tests for viral RNA are done by reverse transcription (RT) of viral RNA to DNA followed by DNA amplification, usually by the polymerase chain reaction (PCR) [@DOI:10.1038/jid.2013.1].
Tests for viral proteins are most often done using detection by an antibody pair in lateral flow tests (LFTs) [@doi:10.1007/s00216-010-3661-4].
Molecular tests require the viral genome sequence to develop DNA primers for viral RNA detection, or to express a viral protein for use as an antigen in antibody production.

Serological tests detect the presence of antibodies in blood plasma samples using enzyme-linked immunosorbent assay (ELISA), lateral flow immunoassay (LFIA), and chemiluminescence immunoassay (CLIA) [@DOI:10.3389/fmolb.2021.682405].
Because vaccines are based on the viral spike protein, to distinguish past infection from vaccination, serology tests look for antibodies that bind the nucleocapsid protein of the SARS-CoV-2 virus [@doi:10.1093/infdis/jiaa273].
Serological tests are useful for collecting population-level information for epidemiological analysis, as they can be used to estimate the extent of the infection in a given area.
Thus, serological tests may be useful to better understand the percent of cases that manifest as severe versus mild and for guiding public health and economic decisions regarding resource allocation and counter-disease measures.
<!-- To Do: How did we discover the identity of these to start binding them?-->
As the pandemic has evolved throughout 2020 and 2021, a variety of technological implementations have emerged within these two categories.

<!-- To Do: Discuss HCoV broadly and the potential risk of detecting other coronaviruses-->
<!-- To Do: Trade offs in cost vs precision (throughput)-->
<!-- To Do: Discuss viral load vs contagiousness vs symptoms vs antibody development? -->
Expand All @@ -40,21 +43,27 @@ Policy discussions have also reviewed both the critical importance of diagnostic
Molecular tests are used to identify distinct genomic subsequences of a viral molecule in a sample and thus to diagnose an active viral infection.
An important first step is identifying which biospecimens are likely to contain the virus in infected individuals and then acquiring these samples from the patient(s) to be tested.
Common sampling sources for molecular tests include nasopharyngeal cavity samples, such as throat washes, throat swabs, and saliva [@doi:10/ggp4qx], and stool samples [@doi:10.1002/jmv.25742].
Once a sample from an appropriate source is acquired from a patient, molecular tests follow a number of different steps, described below, to analyze a sample and identify whether evidence of SARS-CoV-2 is present.
When testing for RNA viruses like SARS-CoV-2, the first step involves pre-processing in order to create complimentary DNA (cDNA) from the RNA sample using reverse transcription (RT).
Once a sample is acquired from a patient, molecular tests detect SARS-CoV-2 based on the presence of either (1) viral nucleic acids or (2) viral protein.

#### Nucleic Acid Tests
When testing for RNA from viruses like SARS-CoV-2, the first step involves pre-processing in order to create complimentary DNA (cDNA) from the RNA sample using reverse transcription (RT).
The second step involves the amplification of a region of interest in the cDNA using successive cycles of heating and cooling.
Depending on the application, different polymerase chain reaction (PCR) procedures exist, which are described below.
Depending on the application, amplification is achieved using variations of the polymerase chain reaction (PCR).
Nucleic acid tests differ primarily in detection methods, which are detailed below.

##### Sequencing
Some tests use the results of the PCR itself to determine whether the pathogen is present, but in other cases, it may be necessary to sequence the amplified DNA.
For sequencing, an additional pre-processing step, library preparation, therefore must be undertaken.
Sequencing requires an additional sample pre-processing step called library preparation.
Library preparation is the process of preparing the sample for sequencing, typically by fragmenting the sequences and adding adapters [@doi:10.1016/j.biotechadv.2020.107537].
In some cases, library preparation can involve other modifications of the sample, such as adding barcodes to identify a particular sample within the sequence data.
Barcoding can therefore be used to pool samples from multiple sources.
There are different reagents used for library preparation that are specific to identifying one or more target sections with PCR [@doi:10.1021/acsnano.0c02624].
Sequential pattern matching is then used to identify unique subsequences of the virus, and if sufficient subsequences are found, the test is considered positive.
Therefore, tests that utilize sequencing require a number of additional molecular and analytical steps relative to tests that use PCR alone.
Sequencing has been an important strategy for discovery of SARS-CoV-2 variants (for example, see [@DOI:10.1101/2021.01.18.21249786]).
<!-- To Do: What is the advantage of the sequencing-based tests?-->

#### RT-PCR
##### RT-PCR

<!-- To Do: Check that all of these RT-PCR definitions are consistent, they seem to vary a little across sections... real time or reverse transcriptase?-->
Reverse Transcription Polymerase Chain Reaction (RT-PCR) tests determine whether a target is present by amplifying a region of interest of cDNA [@doi:10.1042/BIO20200034].
Expand All @@ -65,7 +74,7 @@ Specifically this test utilizes two probes against RdRP, one of which is specifi
Importantly, this assay was not found to return false positive results.
<!-- To Do: How has this changed in the past year? Are we worried about viral evolution? Mention this approach is specific to SARS-CoV-2 rather than other HCoV-->

#### qPCR
##### qPCR

In this manuscript we refer to quantitative real-time PCR as qPCR, following the recommendations of the MIQE guidelines [@doi:10.1373/clinchem.2008.112797].
In contrast to RT-PCR, qPCR uses fluorescent dyes that bind to the amplified DNA, thereby allowing a real time assessment of the amplification procedure [@doi:10.1042/BIO20200034].
Expand Down Expand Up @@ -110,7 +119,35 @@ This evidence further indicates that the lower limit of detection made possible
Overall, these studies suggest that ddPCR is a promising tool for overcoming the problem of false-negative SARS-CoV-2 testing.
<!-- To Do: Should we mention the differences in viral load threshhold for these two methods? We could tie this in to how we don't actually know how the viral load relates to infectiousness-->

#### Pooled and Automated PCR Testing

##### RT-LAMP
RT-PCR remains the gold standard for detection of SARS-CoV-2 RNA from infected patients, but the traditional method requires special equipment and reagents, especially a thermocycler.
Loop mediated isothermal amplification (LAMP) is an alternative to PCR that does not require a thermal cycler [@DOI:10.1093/nar/28.12.e63].
LAMP is combined with reverse transcription (RT-LAMP) to enable detection of RNA.
RT-LAMP pilot studies for detecion of SARS-CoV-2 were recently reviewed and meta-analyzed [@PMID:34086539].
In the meta analysis of all 2,112 samples, the cumulative sensitivity of RT-LAMP was 95.5% (CI 97.5% = 90.8-97.9%) and the cumulative specificity was 99.5% (CI 97.5% = 97.7-99.9%).
The low cost, excellent sensitity/specificity, and quick readout of RT-LAMP makes this an attractive alternative to RT-PCR.
Alternative strategies like RT-LAMP are needed to bring widespread testing away from the lab and into under resourced areas.

One study showed that RT-LAMP is effective for detection of SARS-CoV-2 with excellent specificity and sensitivity, and that this method can be applied to unprocessed saliva samples [@doi:10.1038/s41598-021-95799-6].
This test aims to bring the sensitivity of nucleic acid detection to the point of care or home testing setting.
It could be applied for screening, diagnostics, or as a definitive test for people who are positive based on lateral flow tests.
This method was benchmarked against RT-PCR using 177 human nasopharyngeal RNA samples, of which 126 were COVID positive.
The authors break down the sensitivity of their test according to the cycle threshold (C~t~) value from RT-PCR of the same samples; RT-LAMP performs at 100% sensitivity for samples with a C~t~ from RT-PCR of 32 or less.
The performance is worse when considering all RT-PCR positive samples (including those with C~t~ values between 32-40).
However, there is some evidence suggesting that samples obtained from individuals that achieve C~t~ values >30 measured using RT-PCR tend to be less infective that those that record a C~t~ value <30 [@doi:10.1016/j.jiph.2021.08.013; @doi:10.1017/ice.2021.132; @doi:10.1093/cid/ciaa619], so RT-LAMP is still a useful diagnostic tool.
Various combinations of reagents are available, but one example of reagents being used are the WarmStart Colorimetric LAMP 2X Master Mix with a set of six primers developed previously by Zhang et al. [@doi:10.1101/2020.02.26.20028373].
To determine assay sensitivity, serial tenfold dilutions of _in vitro_ transcribed N-gene RNA standard (IVT RNA) were tested using quantities from 10^5 copies down to 10 copies.
The assay readout is the color of the dye changing from pink to yellow due to binding to the DNA product over 30 minutes.
The RT-LAMP assay was then applied to clinical nasopharyngeal samples.
For viral loads above 100 copies of genomic RNA, the RT-LAMP assay had a sensitivity of 100% and a specificity of 96.1% from purified RNA.
The direct assay of saliva by RT-LAMP had a sensitivity of 85% (CI 70-93%).
Sensitivity and specificity metrics were obtained by comparison with results from RT-PCR.
The estimated cost per test is about 2 euros when RNA extraction is included.
The main strength of this test over RT-PCR is that it can be done isothermally, but the main drawback is that it is about 10-fold less sensitive than RT-PCR.


##### Pooled and Automated PCR Testing

Due to limited supplies and the need for more tests, several labs have found ways to pool or otherwise strategically design tests to increase throughput.
The first such result came from Yelin et al. [@doi:10.1101/2020.03.26.20039438], who found they could pool up to 32 samples in a single qPCR run.
Expand All @@ -121,6 +158,7 @@ Technology based on CRISPR (clustered regularly interspaced short palindromic re

##### CRISPR-based Detection

Technology based on CRISPR (clustered regularly interspaced short palindromic repeats) [@doi:10.1038/s41467-018-04252-2] has also been instrumental in scaling up testing protocols.
Two CRISPR-associated nucleases, Cas12 and Cas13, have been used for nucleic acid detection.
Multiple assays exploiting these nucleases have emerged as potential diagnostic tools for the rapid detection of SARS-CoV-2 genetic material and therefore SARS-CoV-2 infection.
The SHERLOCK method (Specific High-sensitivity Enzymatic Reporter unLOCKing) from Sherlock Biosciences relies on Cas13a to discriminate between inputs that differ by a single nucleotide at very low concentrations [@doi:10.1126/science.aam9321].
Expand Down Expand Up @@ -180,6 +218,20 @@ Lateral flow strips showed a 100% correlation to the high-throughput DETECTR ass
Importantly, DETECTR was 100% specific for SARS-CoV-2 and did not detect other human coronaviruses.
A method based on a Cas9 ortholog from Francisella novicida (FnCas9) achieved 100% sensitivity and 97% specificity in clinical samples, and the diagnostic kit is reported to have completed regulatory validation in India [@doi:10.1101/2020.09.13.20193581].

#### Protein tests
LFT-based tests are beneficial because they can detect current infection within 30 minutes and because they can be performed without specialized equipment at low cost.
LFTs rely on the detection of viral protein with an antibody.
Often this is done with an antibody sandwich format, where one antibody containing a dye binds at one site on the antigen, and an immobilized antibody on the strip binds at another site, allowing accumulation of the dye and the characteristic formation of a positive test line on the strip [@doi:10.1007/s00216-010-3661-4].
The applications of LFTs are broad; they are routinely used for home pregnancy tests, disease detection, and even drugs of abuse detection in urine [@DOI:10.1007/s00216-008-2287-2].
Current infection detection by LFTs is needed to enable the scale and speed of testing required to stop the spread of SARS-CoV-2.
LFTs were made available freely to citizens in the United Kingdom at least until December 2021 [@DOI:10.1136/bmj.n1760].

A recent review surveyed the performance of LFTs for detection of current SARS-CoV-2 infection [@PMID:34407759].
This review covered 24 studies that included more than 26,000 total LFTs.
They found significant heterogeneity in test sensitivities ranging from 37.7% (95% CI 30.6-45.5) to 99.2% (95% CI 95.5-99.9).
The specificities of these tests were more homogeneous, spanning 92.4% (95% CI 87.5-95.5) to 100.0% (95% CI 99.7-100.0).
<!-- To do: examples of specific studies evaluating LFTs for covid detection -->

#### Limitations of Molecular Tests

Tests that identify SARS-CoV-2 using nucleic-acid-based technologies will identify only individuals with current infections and are not appropriate for identifying individuals who have recovered from a previous infection.
Expand Down
17 changes: 17 additions & 0 deletions content/metadata.yaml
Original file line number Diff line number Diff line change
Expand Up @@ -1387,3 +1387,20 @@ authors:
order: 1
contributions:
- Writing - Review & Editing
-
github: jessegmeyerlab
name: Jesse G. Meyer
initials: JGM
orcid: 0000-0003-2753-3926
email: [email protected]
affiliations:
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America
coi:
string: "None"
Copy link
Contributor

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

@jessegmeyerlab The only other thing I need from you is just any disclosure of conflicts of interest -- or just okay the "None" I have here!

Copy link
Contributor Author

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

I do not have any conflicts of interest

Copy link
Contributor

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Sounds great! I'm merging it in now :)

lastapproved: !!str 2022-01-06
manuscripts:
diagnostics:
order: 1
contributions:
- Writing - Review & Editing
- Writing - Original Draft